{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:10:48Z","timestamp":1789938648608,"version":"4.0.1"},"reference-count":101,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2017,1,19]],"date-time":"2017-01-19T00:00:00Z","timestamp":1484784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Cancer is a devastating disease that affects millions of patients every year, and causes an enormous economic burden on the health care system and emotional burden on affected families. The first line of defense against solid tumors is usually extraction of the tumor, when possible, by surgical methods. In cases where solid tumors can not be safely removed, chemotherapy is often the first line of treatment. As metastatic cancers often become vigorously resistant to treatments, the development of novel, more potent and selective anti-cancer strategies is of great importance. Adenovirus (Ad) is the most commonly used virus in cancer clinical trials, however, regardless of the nature of the Ad-based therapeutic, complete responses to treatment remain rare. A number of pre-clinical studies have shown that, for all vector systems, viral spread throughout the tumor mass can be a major limiting factor for complete tumor elimination. By expressing exogenous cell-fusion proteins, many groups have shown improved spread of Ad-based vectors. This review summarizes the research done to examine the potency of Ad vectors expressing fusogenic proteins as anti-cancer therapeutics.<\/jats:p>","DOI":"10.3390\/v9010013","type":"journal-article","created":{"date-parts":[[2017,1,19]],"date-time":"2017-01-19T10:55:40Z","timestamp":1484823340000},"page":"13","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Adenoviral Vectors Armed with Cell Fusion-Inducing Proteins as Anti-Cancer Agents"],"prefix":"10.3390","volume":"9","author":[{"given":"Joshua","family":"Del Papa","sequence":"first","affiliation":[{"name":"Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada"},{"name":"Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1N 6N5, Canada"},{"name":"Centre for Neuromuscular Disease, University of Ottawa, Ottawa, ON K1N 6N5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Parks","sequence":"additional","affiliation":[{"name":"Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada"},{"name":"Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1N 6N5, Canada"},{"name":"Centre for Neuromuscular Disease, University of Ottawa, Ottawa, ON K1N 6N5, Canada"},{"name":"Department of Medicine, University of Ottawa, Ottawa, ON K1N 6N5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,1,19]]},"reference":[{"key":"ref_1","first-page":"1","article-title":"Global cancer facts & figures 2007","volume":"1","author":"Garcia","year":"2007","journal-title":"Atlanta GA Am. Cancer Soc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Schwab, M. (2008). Encyclopedia of Cancer, Springer.","DOI":"10.1007\/978-3-540-47648-1"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/pbc.24487","article-title":"Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors","volume":"60","author":"Green","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1093\/emboj\/cdf595","article-title":"\u2018Super p53\u2019 mice exhibit enhanced DNA damage response, are tumor resistant and age normally","volume":"21","author":"Criado","year":"2002","journal-title":"EMBO J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of cancer drug resistance","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"ref_8","first-page":"1161","article-title":"Adenoviral gene therapy for cancer: From vectors to targeted and replication competent agents (review)","volume":"21","author":"Bauerschmitz","year":"2002","journal-title":"Int. J. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1172\/JCI9762","article-title":"Replication-selective adenoviruses as oncolytic agents","volume":"105","author":"Heise","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Kirn, D.H., Wang, Y., Le Boeuf, F., Bell, J., and Thorne, S.H. (2007). Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med, 4.","DOI":"10.1371\/journal.pmed.0040353"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","article-title":"Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor\u2013encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma","volume":"27","author":"Senzer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.molmed.2004.03.003","article-title":"Vesicular stomatitis virus: Re-inventing the bullet","volume":"10","author":"Lichty","year":"2004","journal-title":"Trends Mol. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/78638","article-title":"A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer","volume":"6","author":"Khuri","year":"2000","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40265-015-0522-7","article-title":"Talimogene laherparepvec: First global approval","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1089\/hum.2005.16.1016","article-title":"Current status of gendicine in China: Recombinant human Ad-p53 agent for treatment of cancers","volume":"16","author":"Peng","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"ref_16","first-page":"1666","article-title":"Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus","volume":"23","author":"Xia","year":"2004","journal-title":"Chin. J. Cancer"},{"key":"ref_17","unstructured":"Edelstein, M. Gene Therapy Clinical Trials Worldwide. Available online: http:\/\/www.abedia.com\/wiley\/."},{"key":"ref_18","first-page":"7464","article-title":"A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy","volume":"61","author":"DeWeese","year":"2001","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/B:NEON.0000003653.45635.32","article-title":"Clinical trials of adenoviruses in brain tumors: A review of Ad-p53 and oncolytic adenoviruses","volume":"65","author":"Vecil","year":"2003","journal-title":"J. Neuro-Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/104303403321467199","article-title":"Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: Virus persists and spreads systemically at late time points","volume":"14","author":"Sauthoff","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1089\/104303401750270977","article-title":"Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved-deletion of the viral E1b-19-kD gene increases the viral oncolytic effect","volume":"12","author":"Harrison","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/mt.2010.79","article-title":"Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth","volume":"18","author":"Guedan","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1158\/0008-5472.CAN-03-3882","article-title":"An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated Wnt signaling","volume":"64","author":"Toth","year":"2004","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1089\/hum.2016.022","article-title":"Epithelial Junction Opener Improves Oncolytic Adenovirus Therapy in Mouse Tumor Models","volume":"27","author":"Yumul","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"9706","DOI":"10.1128\/JVI.72.12.9706-9713.1998","article-title":"An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism","volume":"72","author":"Dmitriev","year":"1998","journal-title":"J. Virol."},{"key":"ref_26","first-page":"325","article-title":"Loss of adenoviral receptor expression in human bladder cancer cells: A potential impact on the efficacy of gene therapy","volume":"59","author":"Li","year":"1999","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1128\/JVI.73.6.5156-5161.1999","article-title":"RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection","volume":"73","author":"Vigne","year":"1999","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"10074","DOI":"10.1128\/JVI.02665-09","article-title":"Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX","volume":"84","author":"Poulin","year":"2010","journal-title":"J. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.virol.2011.09.004","article-title":"Use of Cre\/loxP recombination to swap cell binding motifs on the adenoviral capsid protein IX","volume":"420","author":"Poulin","year":"2011","journal-title":"Virology"},{"key":"ref_30","first-page":"351","article-title":"Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States","volume":"11","author":"Nwanegbo","year":"2004","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"Mast","year":"2010","journal-title":"Vaccine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7199","DOI":"10.1158\/1078-0432.CCR-04-0765","article-title":"Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model","volume":"10","author":"Tsai","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_33","first-page":"2355","article-title":"Adenoviridae: The viruses and their replication","volume":"2","author":"Martin","year":"2007","journal-title":"Fields\u2019 Virology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/rmv.386","article-title":"The impact of adenovirus infection on the immunocompromised host","volume":"13","author":"Kojaoghlanian","year":"2003","journal-title":"Rev. Med. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/nar\/gkr1076","article-title":"Chromatin structure of adenovirus DNA throughout infection","volume":"40","author":"Giberson","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1099\/vir.0.19497-0","article-title":"Genetic content and evolution of adenoviruses","volume":"84","author":"Davison","year":"2003","journal-title":"J. Gen. Virol."},{"key":"ref_37","unstructured":"Ng, P., and Brunetti-Pierri, N. (2016). Gene Therapy with Adenoviral Based Vectors, Taylor and Francis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1128\/JVI.01644-08","article-title":"DNA genome size affects the stability of the adenovirus virion","volume":"83","author":"Smith","year":"2009","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9086","DOI":"10.1128\/JVI.01024-08","article-title":"Presence of the adenovirus IVa2 protein at a single vertex of the mature virion","volume":"82","author":"Christensen","year":"2008","journal-title":"J. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0092-8674(86)90460-5","article-title":"A mechanism for the control of protein synthesis by adenovirus VA RNA I","volume":"44","author":"Mariano","year":"1986","journal-title":"Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/JVI.80.3.1376-1384.2006","article-title":"Adenovirus virus-associated RNA is processed to functional interfering RNAs involved in virus production","volume":"80","author":"Aparicio","year":"2006","journal-title":"J. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.3390\/v6093563","article-title":"The adenovirus genome contributes to the structural stability of the virion","volume":"6","author":"Saha","year":"2014","journal-title":"Viruses"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"8902","DOI":"10.1128\/jvi.71.11.8902-8907.1997","article-title":"Persistence of recombinant adenovirus in vivo is not dependent on vector DNA replication","volume":"71","author":"Nelson","year":"1997","journal-title":"J. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ygyno.2004.05.041","article-title":"A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum-and paclitaxel-resistant epithelial ovarian cancer","volume":"94","author":"Wolf","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1096\/fj.02-0900fje","article-title":"Overexpression of interleukin-12 enables dendritic cells to activate NK cells and confer systemic antitumor immunity","volume":"17","author":"Miller","year":"2003","journal-title":"FASEB J."},{"key":"ref_46","first-page":"2559","article-title":"Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells","volume":"57","author":"Rodriguez","year":"1997","journal-title":"Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ding, M., Cao, X., Xu, H.-N., Fan, J.-K., Huang, H.-L., Yang, D.-Q., Li, Y.-H., Wang, J., Li, R., and Liu, X.-Y. (2012). Prostate cancer-specific and potent antitumor effect of a DD3-controlled oncolytic virus harboring the PTEN gene. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035153"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/351494a0","article-title":"Adenovirus E1a prevents the retinoblastoma gene product from complexing with a cellular transcription factor","volume":"351","author":"Bandara","year":"1991","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1593\/neo.04793","article-title":"Downmodulation of El A Protein Expression as a Novel Strategy to Design Cancer-Selective Adenoviruses","volume":"7","author":"Jiang","year":"2005","journal-title":"Neoplasia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/hmg\/10.7.699","article-title":"The Rb\/E2F pathway and cancer","volume":"10","author":"Nevins","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.3748\/wjg.v10.i24.3634","article-title":"Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: A pilot phase II clinical trial","volume":"10","author":"Lu","year":"2004","journal-title":"World J. Gastroenterol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/sj.cgt.7700071","article-title":"Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects","volume":"6","author":"Heise","year":"1999","journal-title":"Cancer Gene Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1200\/JCO.2003.21.13.2508","article-title":"Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: Biological and clinical results","volume":"21","author":"Lang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1089\/hum.2010.227","article-title":"Strategies to enhance viral penetration of solid tumors","volume":"22","author":"Smith","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0042-6822(89)90236-5","article-title":"Genetic organization of gibbon ape leukemia virus","volume":"173","author":"Delassus","year":"1989","journal-title":"Virology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/v8040112","article-title":"Measles Virus Fusion Protein: Structure, Function and Inhibition","volume":"8","author":"Plattet","year":"2016","journal-title":"Viruses"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"14172","DOI":"10.1073\/pnas.260499197","article-title":"Structural characterization of the human respiratory syncytial virus fusion protein core","volume":"97","author":"Zhao","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/emboj\/19.5.902","article-title":"A new class of fusion-associated small transmembrane (FAST) proteins encoded by the non-enveloped fusogenic reoviruses","volume":"19","author":"Shmulevitz","year":"2000","journal-title":"EMBO J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nsmb.1455","article-title":"Mechanics of membrane fusion","volume":"15","author":"Chernomordik","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_60","first-page":"1492","article-title":"Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth","volume":"60","author":"Bateman","year":"2000","journal-title":"Cancer Res."},{"key":"ref_61","first-page":"6566","article-title":"Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells","volume":"62","author":"Bateman","year":"2002","journal-title":"Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Wong, C.M., Poulin, K.L., Tong, G., Christou, C., Kennedy, M.A., Falls, T., Bell, J.C., and Parks, R.J. (2016). Adenovirus-Mediated Expression of the p14 Fusion-Associated Small Transmembrane Protein Promotes Cancer Cell Fusion and Apoptosis In Vitro but Does Not Provide Therapeutic Efficacy in a Xenograft Mouse Model of Cancer. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0151516"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"8090","DOI":"10.1128\/JVI.79.13.8090-8100.2005","article-title":"Extensive syncytium formation mediated by the reovirus FAST proteins triggers apoptosis-induced membrane instability","volume":"79","author":"Salsman","year":"2005","journal-title":"J. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.canlet.2008.07.035","article-title":"Inhibition of NF-\u03baB in fusogenic membrane glycoprotein causing HL-60 cell death: Implications for acute myeloid leukemia","volume":"273","author":"Tan","year":"2009","journal-title":"Cancer Lett."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/jgm.616","article-title":"Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas","volume":"6","author":"Allen","year":"2004","journal-title":"J. Gene Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1089\/104303403321467216","article-title":"Heat-directed tumor cell fusion","volume":"14","author":"Brade","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/mt.2010.209","article-title":"Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia","volume":"19","author":"Chen","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/sj.gt.3302064","article-title":"Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy","volume":"10","author":"Ahmed","year":"2003","journal-title":"Gene Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/gt.2008.94","article-title":"Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication","volume":"15","author":"Guedan","year":"2008","journal-title":"Gene Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/gt.2011.184","article-title":"GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution","volume":"19","author":"Guedan","year":"2012","journal-title":"Gene Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/0042-6822(90)90207-8","article-title":"Intracellular processing, glycosylation, and cell-surface expression of the measles virus fusion protein (F) encoded by a recombinant adenovirus","volume":"175","author":"Alkhatib","year":"1990","journal-title":"Virology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1089\/104303401750148766","article-title":"Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas","volume":"12","author":"Galanis","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.3748\/wjg.v13.i22.3063","article-title":"In situ tumor vaccination with adenovirus vectors encoding measles virus fusogenic membrane proteins and cytokines","volume":"13","author":"Hoffmann","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1158\/1535-7163.MCT-06-0128","article-title":"Enhanced killing of pancreatic cancer cells by expression of fusogenic membrane glycoproteins in combination with chemotherapy","volume":"5","author":"Hoffmann","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/sj.gt.3302806","article-title":"Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer","volume":"13","author":"Hoffmann","year":"2006","journal-title":"Gene Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/sj.jid.5701131","article-title":"Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma","volume":"128","author":"Hoffmann","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1158\/1535-7163.MCT-06-0790","article-title":"Intratumoral expression of respiratory syncytial virus fusion protein in combination with cytokines encoded by adenoviral vectors as in situ tumor vaccine for colorectal cancer","volume":"6","author":"Hoffmann","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_78","first-page":"673","article-title":"Therapeutic immune response induced by intratumoral expression of the fusogenic membrane protein of vesicular stomatitis virus and cytokines encoded by adenoviral vectors","volume":"20","author":"Hoffmann","year":"2007","journal-title":"Int. J. Mol. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/jgm.371","article-title":"Effects of adenovirus-mediated SV5 fusogenic glycoprotein expression on tumor cells","volume":"5","author":"Castel","year":"2003","journal-title":"J. Gene Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/cgt.2016.41","article-title":"Expression of the fusogenic p14 FAST protein from a replication-defective adenovirus vector does not provide a therapeutic benefit in an immunocompetent mouse model of cancer","volume":"23","author":"Wong","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1128\/jvi.63.6.2452-2456.1989","article-title":"Biosynthesis and processing of human immunodeficiency virus type 1 envelope glycoproteins: Effects of monensin on glycosylation and transport","volume":"63","author":"Dewar","year":"1989","journal-title":"J. Virol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1089\/10430340152710504","article-title":"Human immunodeficiency virus type 1-mediated syncytium formation is compatible with adenovirus replication and facilitates efficient dispersion of viral gene products and de novo-synthesized virus particles","volume":"12","author":"Li","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1073\/pnas.91.3.1168","article-title":"A human amphotropic retrovirus receptor is a second member of the gibbon ape leukemia virus receptor family","volume":"91","author":"Johann","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/ki.1996.135","article-title":"Identification and characterization of a widely expressed phosphate transporter\/retrovirus receptor family","volume":"49","author":"Kavanaugh","year":"1996","journal-title":"Kidney Int."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/sj.gt.3300420","article-title":"Novel retroviral packaging cell lines: Complementary tropisms and improved vector production for efficient gene transfer","volume":"4","author":"Forestell","year":"1997","journal-title":"Gene Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1089\/10430340050015437","article-title":"A hyperfusogenic gibbon ape leukemia envelope glycoprotein: Targeting of a cytotoxic gene by ligand display","volume":"11","author":"Fielding","year":"2000","journal-title":"Hum. Gene Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/sj.gt.3301951","article-title":"Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction","volume":"10","author":"Johnson","year":"2003","journal-title":"Gene Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1470-2045(02)00818-5","article-title":"Hyperthermia in combined treatment of cancer","volume":"3","author":"Wust","year":"2002","journal-title":"Lancet Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Griffin, D.E., and Oldstone, M.B. (2008). Measles: History and Basic Biology, Springer. [1st ed.].","DOI":"10.1007\/978-3-540-70523-9"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nbt942","article-title":"Antibody-targeted cell fusion","volume":"22","author":"Nakamura","year":"2004","journal-title":"Nat. Biotechnol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1128\/JVI.75.5.2087-2096.2001","article-title":"Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen","volume":"75","author":"Hammond","year":"2001","journal-title":"J. Virol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1182\/blood-2002-07-2195","article-title":"Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker","volume":"101","author":"Peng","year":"2003","journal-title":"Blood"},{"key":"ref_93","first-page":"5495","article-title":"Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion","volume":"62","author":"Linardakis","year":"2002","journal-title":"Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1128\/JVI.01921-08","article-title":"The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis","volume":"83","author":"Brown","year":"2009","journal-title":"J. Virol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1535-6108(03)00241-1","article-title":"VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents","volume":"4","author":"Stojdl","year":"2003","journal-title":"Cancer Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/mt.2010.44","article-title":"Synergistic interaction between oncolytic viruses augments tumor killing","volume":"18","author":"Diallo","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/0092-8674(95)90076-4","article-title":"Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species soecificity","volume":"81","author":"Symons","year":"1995","journal-title":"Cell"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1128\/jvi.67.10.5911-5921.1993","article-title":"Packaging capacity and stability of human adenovirus type 5 vectors","volume":"67","author":"Bett","year":"1993","journal-title":"J. Virol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/mt.2009.202","article-title":"Adenovirus virion stability and the viral genome: Size matters","volume":"17","author":"Kennedy","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1089\/hum.1995.6.6-711","article-title":"Trans-complementation of E1-deleted adenovirus: A new vector to reduce the possibility of codissemination of wild-type and recombinant adenoviruses","volume":"6","author":"Imler","year":"1995","journal-title":"Hum. Gene Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/jgm.384","article-title":"A tetracycline-regulated adenoviral expression system for in vivo delivery of transgenes to lung and liver","volume":"5","author":"Tietge","year":"2003","journal-title":"J. Gene Med."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/9\/1\/13\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:26:34Z","timestamp":1760207194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/9\/1\/13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,19]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1]]}},"alternative-id":["v9010013"],"URL":"https:\/\/doi.org\/10.3390\/v9010013","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,19]]}}}